DVA DaVita
A mature, levered dialysis duopolist whose pricing power and buybacks outrun stagnant volumes; modestly undervalued.
The story
DaVita is the #2 US dialysis provider in a two-player market alongside Fresenius. Its moat comes from scale, clinic density, and payer contracting leverage. The business is mature: patient volumes are flat to slightly down, and growth comes from rate increases, integrated kidney care, and modest international expansion. Commercial payers subsidize a Medicare book that barely breaks even, and heavy debt-funded buybacks (with Berkshire as anchor holder) amplify per-share results.
Growth of about 4.5% is mostly pricing and mix, since treatment volumes are stagnant, so it fades to 2.5% terminal, below the risk-free rate. Margin holds near the 14% TTM level rather than the 15.6% peak, because labor costs and Medicare Advantage rate pressure cap expansion. Beta sits above the 0.9 industry anchor to reflect net debt of about $9.6B against an $11B equity cap, and the 3% failure probability covers that leverage plus reimbursement policy risk.
Value drivers
| Revenue growth (Y1) | 4.5% |
| Terminal growth | 2.5% |
| Forecast horizon | 6y |
| Target operating margin | 14.0% |
| Years to target margin | 3 |
| Sales-to-capital | 1.40 |
| Beta | 1.05 |
| Failure probability | 3.0% |
| Cost of capital (WACC) | 8.5% |
| Terminal WACC | 8.3% |
Valuation bridge
| PV of explicit FCFF | 6.12B |
| PV of terminal value | 16.58B |
| Equity value | 9.57B |
| ÷ shares → per share | $149.96 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 14.46B | 4.5% | 14.3% | 1.61B | 444.70M | 1.17B | 1.08B |
| 2 | 15.05B | 4.1% | 14.1% | 1.66B | 423.40M | 1.24B | 1.05B |
| 3 | 15.61B | 3.7% | 14.0% | 1.71B | 397.76M | 1.31B | 1.03B |
| 4 | 16.12B | 3.3% | 14.0% | 1.77B | 367.89M | 1.40B | 1.01B |
| 5 | 16.59B | 2.9% | 14.0% | 1.82B | 333.96M | 1.48B | 988.30M |
| 6 | 17.00B | 2.5% | 14.0% | 1.86B | 296.25M | 1.57B | 962.31M |
Key risks
- GLP-1s and SGLT2 drugs slow CKD progression, shrinking the dialysis patient census
- Commercial payer mix erodes or Medicare/MA rates lag wage inflation, compressing the subsidy that funds profits
- Leverage near 3.5x EBITDA leaves little cushion if a policy shock or cyber event (as in 2025) hits cash flow
Catalysts
- Continued aggressive buybacks retiring 8-10% of shares annually at a discount to intrinsic value
- Treatment volume stabilization plus integrated kidney care and international profitability improving the growth mix